Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Observer-Blind, Controlled, Single Center Study to Evaluate the Safety and Immunogenicity of Three Formulations of the NVGH Glycoconjugate Vaccine Against S. Typhi in Adult Subjects 18 to 40 Years of Age.

Next Previous
Search
Trial Profile

A Phase 2, Randomized, Observer-Blind, Controlled, Single Center Study to Evaluate the Safety and Immunogenicity of Three Formulations of the NVGH Glycoconjugate Vaccine Against S. Typhi in Adult Subjects 18 to 40 Years of Age.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 14 Jan 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Typhoid vaccine Vi conjugate (Primary) ; Typhoid vaccine Vi-polysaccharide
  • Indications Typhoid
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Novartis

Most Recent Events

  • 12 Oct 2012 New source identified and integrated (extension trial: EudraCT2011-001448-31).
  • 12 Oct 2012 New source identified and integrated (extension trial: EudraCT2011-001448-31).
  • 09 Dec 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov (Extension trial: NCT01438996).

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top